Acadia Pharmaceuticals sell The Goldman Sachs Group, Inc.
Start price
07.08.25
/
50%
€20.93
Target price
07.08.26
€14.58
Performance (%)
-9.03%
Price
25.03.26
€19.04
Summary
This prediction is currently active. With a performance of -9.03%, the SELL prediction by The_Goldman_Sachs_Gr is trending in the right direction. This prediction currently runs until 07.08.26. The prediction end date can be changed by The_Goldman_Sachs_Gr at any time. The_Goldman_Sachs_Gr has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Acadia Pharmaceuticals | 7.540% | 7.540% |
| iShares Core DAX® | -1.034% | -9.171% |
| iShares Nasdaq 100 | -1.947% | -2.616% |
| iShares Nikkei 225® | -0.425% | -9.424% |
| iShares S&P 500 | -1.201% | -2.986% |
Comments by The_Goldman_Sachs_Gr for this prediction
In the thread Acadia Pharmaceuticals diskutieren
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $15.00 to $17.00. They now have a "sell" rating on the stock.
Ratings data for ACAD provided by MarketBeat